Nocturia: Etiology, diagnosis, and treatment

Neurourology and Urodynamics

Volumn 27, Issue 1, 2008, Pages 34-39

  Appell, Rodney A ^a   Sand, Peter K ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antimuscarinics; Diagnosis; Nocturia

Indexed keywords

ARGIPRESSIN; BOTULINUM TOXIN; DARIFENACIN; DESMOPRESSIN ACETATE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

BEHAVIOR CHANGE; BLADDER CAPACITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DRUG TOLERABILITY; EARLY DIAGNOSIS; HEADACHE; HUMAN; HYPONATREMIA; INCIDENCE; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; NAUSEA; NOCTURIA; OVERACTIVE BLADDER; PHYSICAL EXAMINATION; POLYURIA; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MUSCARINIC ANTAGONISTS; NOCTURIA; QUALITY OF LIFE; URINARY BLADDER;

EID: 37849005224     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20484     Document Type: Review

References (56)

1. Van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardization of terminology in nocturia: Report from the standardization subcommittee of the International Continence Society. BJU Int 2002;90:11-5.
2. Coyne KS, Zhou Z, Bhattacharyya SK, et al. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int 2003;92:948-54.
3. Schatzl G, Temml C, Schmidbauer J, et al. Cross-sectional study of nocturia in both sexes: Analysis of a voluntary health screening project. Urology 2000;56:71-5.
4. Yoshimura K, Terada N, Matsui Y, et al. Prevalence of and risk factors for nocturia: Analysis of a health screening program. Int J Urol 2004;11:282-7.
5. Jolleys JV, Donovan JL, Nanchahal K, et al. Urinary symptoms in the community: How bothersome are they? Br J Urol 1994;74:551-55.
6. Swithinbank L, Donovan J, James M, et al. Female urinary symptoms: Age prevalence in a community dwelling population using a validated questionnaire. Neurourol Urodyn 1997;16:432-4.
7. Scarpa RM. Lower urinary tract symptoms: What are the implications for the patients? Eur Urol 2001;40:12-20.
8. Marschall-Kehrel D. Update on nocturia: The best of rest is sleep. Urology 2004;64:21-4.
9. Weiss JP, Blaivas JG. Nocturia. J Urol 2000;163:5-12.
10. Stewart RB, Moore MT, May FE, et al. Nocturia: A risk factor for falls in the elderly. J Am Geriatr Soc 1992;40:1217-20.
11. Weiss JP, Blaivas JG. Nocturnal polyuria versus overactive bladder in nocturia. Urology 2002;60:28-32, discussion 32.
12. Asplund R. Nocturia in relation to sleep, health, and medical treatment in the elderly. BJU Int 2005;96:15-21.
13. Sands JM, Bichet DG. for the American College of Physicians and American Physiological Society. Nephrogenic diabetes insipidus. Ann Intern Med 2006;144:186-94.
14. Matthiesen TB, Rittig S, Norgaard JP, et al. Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms. J Urol 1996;156:1292-9.
15. Krieger JN, Petiau C, Sforza E, et al. Nocturnal pollakiuria is a symptom of obstructive sleep apnea. Urol Int 1993;50:93-7.
16. Partinen M. Epidemiology of obstructive sleep apnea syndrome. Curr Opin Pulm Med 1995;1:482-7.
17. Pressman MR, Figueroa WG, Kendrick-Mohamed J, et al. Nocturia A rarely recognized symptom of sleep apnea and other occult sleep disorders. Arch Intern Med 1996;156:545-50.
18. Weiss JP, Blaivas JG, Stember DS, et al. Evaluation of the etiology of nocturia in men: The nocturia and nocturnal bladder capacity indices. Neurourol Urodyn 1999;18:559-65.
19. Rembratt A, Weiss J, Robertson G. Pathogenesis of nocturia in the elderly: Relationship of functional bladder capacity to nocturnal urine output. J Urol 2001;165:250.
20. Pedersen PA, Johansen PB. Prophylactic treatment of adult nocturia with bumetanide. Br J Urol 1988;62:145-7.
21. Lose G, Lalos O, Freeman RM, et al. Efficacy of desmopressin (Minirin) in the treatment of nocturia: A double-blind placebo-controlled study in women. Am J Obstet Gynecol 2003;189:1106-13.
22. Cannon A, Carter PG, McConnell AA, et al. Desmopressin in the treatment of nocturnal polyuria in the male. BJU Int 1999;84:20-4.
23. Mattiasson A, Abrams P, Van Kerrebroeck P, et al. Efficacy of desmopressin in the treatment of nocturia: A double-blind placebo-controlled study in men. BJU Int 2002;89:855-62.
24. Rembratt A, Norgaard JP, Andersson KE. Desmopressin in elderly patients with nocturia: Short-term safety and effects on urine output, sleep and voiding patterns. BJU Int 2003;91:642-6.
25. Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol 2004;172:1021-5.
26. Rembratt A, Riis A, Norgaard JP. Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol Urodyn 2006;25:105-9.
27. Weatherall M. The risk of hyponatremia in older adults using desmopressin for nocturia: A systematic review and meta-analysis. Neurourol Urodyn 2004;23:302-5.
28. Abrams P, Mattiasson A, Lose GR, et al. The role of desmopressin in the treatment of adult nocturia. BJU Int 2002;90:32-6.
29. Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor - which is the main mechanism of action? Eur Urol 2003;43:1-5.
30. Andersson KE. Bladder activation: Afferent mechanisms. Urology 2002;59:43-50.
31. Hegde SS. Muscarinic receptors in the bladder: From basic research to therapeutics. Br J Pharmacol 2006;147:S80-7.
32. Staskin DR, MacDiarmid SA. Using anticholinergics to treat overactive bladder: The issue of treatment tolerability. Am J Med 2006;119:9-15.
33. Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: A multicenter phase III trial. J Urol 2004;171:2311-5.
34. Abrams P, Swift S. Solifenacin is effective for the treatment of OAB dry patients: A pooled analysis. Eur Urol 2005;48:483-7.
35. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial. Eur Urol 2005;48:464-70.
36. Rudy D, Cline K, Harris R, et al. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 2006;67:275-80.
37. 3 selective receptor antagonist for the treatment of overactive bladder: Results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct 2006;17:239-47.
38. 3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004;45:420-9.
39. Johnson TM II, Burgio KL, Redden DT, et al. Effects of behavioral and drug therapy on nocturia in older incontinent women. J Am Geriatr Soc 2005;53:846-50.
40. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005;174:2273-5.
41. Pak RW, Petrou SP, Staskin DR. Trospium chloride: A quaternary amine with unique pharmacologic properties. Curr Urol Rep 2003;4:436-40.
42. Katz IR, Sands LP, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: The case of oxybutynin chloride. J Am Geriatr Soc 1998;46:8-13.
43. Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 2003;349:2274-5.
44. Williams SG, Staudenmeier J. Hallucinations with tolterodine. Psychiatr Serv 2004;55:1318-9.
45. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: Effects of darifenacin. J Urol 2005;173:493-8.
46. Doroshyenko O, Jetter A, Odenthal KP, et al. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet 2005;44:701-20.
47. Pietzko A, Dimpfel W, Schwantes U, et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994;47:337-43.
48. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride and oxybutynin on the central nervous system. J Clin Pharmacol 2001;41:636-44.
49. Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Sci 2004;5:423-6.
50. Diefenbach K, Arold G, Wollny A, et al. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged ≥50 years. BJU Int 2005;95:346-9.
51. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, et al. Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes. Pharmacol Toxicol 1999;85:299-304.
52. Staskin DR. Overactive bladder in the elderly: A guide to pharmacological management. Drugs Aging 2005;22:1013-28.
53. Schulte-Baukloh H, Weiss C, Stolze T, et al. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: Urodynamic outcome and patient satisfaction. Urology 2005;66:82-7.
54. Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005;47:653-9.
55. Kessler TM, Danuser H, Schumacher M, et al. Botulinum A toxin injections into the detrusor: An effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 2005;24:231-6.
56. Rajkumar GN, Small DR, Mustafa AW, et al. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 2005;96:848-52.